Dipyridamole was shown to block neutrophil activation by autoantibodies found in serum from patients hospitalized with COVID-19 (Supp Fig 8) Photo CC-BY Yu Zou, et al.
The chemical structure of dipyridamole.

Dipyridamole, a vasodilator and antiplatelet drug, has been proposed as a possible COVID-19 therapeutic.

Mechanism of potential benefit

Dipyridamole is said to "[have the] potential to inhibit multiple processes that have been recently linked to COVID-19 severity," such as purinergic signaling (related to inflammation and thrombosis), and may help induction of type 1 IFNs.

Dipyridamole has also been shown to have direct anti-viral effects against SARS-CoV-2, showing anti-SARS-CoV-2 activity in vitro in Vero cells. Dipyridamole's anti-SARS-CoV-2 activity may occur via binding to the SARS-CoV-2 protease Mpro (see Fig. 1B).

Research overviews:

Clinical trials

A list of clinical trials of dipyridamole for COVID-19:

Trial results:

A proof-of-concept trial of 31 COVID-19 patients was carried out in China in early 2020, finding signs of potential benefit.

See also